Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours

Athanassiadou, Pauline; Petrakakou, E.; Sakelariou, V; Zerva, Cherry; Liossi, A; Michalas, Stylianos; Athanassiades, P.

doi:10.1097/00008469-199806000-00007

Cited by 33 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest the involvement of the mitochondrial apoptosis pathway in serous tumours. Our results are in line with those of Athanassiadou et al [34] demonstrating that bcl-2 expression is cell-and tissuedependent, and that both p53 and bcl-2 expression are reduced in serous ovarian carcinomas. In addition to p21 expression, our results suggest that serous borderline tumours have a different apoptosis-related protein profile than their mucinous counterparts.…”

Section: Discussionsupporting

confidence: 93%

Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours

et al. 2005

View full text Add to dashboard Cite

show abstract

“…112,113 p53 expression was detected by immunohistochemical staining in all but two studies that used immunofluorometric assays. 83,84 The monoclonal antibodies D0-7 and PAb-1801 (which detect both wildtype and mutant p53 protein) were the most common primary antibodies, and were used in 36 studies 14-16,19, 21,23,25,28,29,32,34,37,38,46,48,52,53,55,72,78,80 -82,85,87,89,92,95 15,17,49,87 Four studies used a combination of paraffin-embedded and frozen tissue, 18,53,82,92 one study used imprints from biopsies, 25 and one study did not report on the tissue type used.…”

Section: Results P53 Protein Expressionmentioning

confidence: 99%

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

Kmet

Cook

Magliocco

2003

Cancer

View full text Add to dashboard Cite

Das rationale Design niedermolekularer Verbindungen, die selektiv auf eine definierte RNA wirken, ist eine schwierige Aufgabe; solche Sonden könnten aber die zeitlich hochaufgelöste Untersuchung von RNA‐Funktionen in Zellen ermöglichen. In der Zuschrift auf identifizieren R. Rodriguez, S. Balasubramanian et al. mit In‐situ‐Klickchemie eine niedermolekulare Substanz, die selektiv mit Telomerwiederholungseinheiten enthaltender RNA (TERRA) über die Erkennung der G‐Quadruplex‐Struktur wechselwirkt. Mit demselben Ansatz wurde ein verwandtes Analogon erkannt, das hoch effizient die entsprechende DNA adressiert.

show abstract

“…This contrasts with a study from Ben-Hur et al [4], Chan et al [6] and Zusman et al [45], showing a decrease in bcl-2 expression from benign to borderline and malignant ovarian tumours. However, bcl-2 expression is cell-and tissue dependent, and both p53 and bcl-2 expression are reduced in serous ovarian carcinomas [1]. Indeed, recently, Nezhat and Kalir [30] have demonstrated a qualitative underexpresssion of bcl-2 in cystic compared with non-cystic endometriotic lesions suggesting a differential expression pattern of bcl-2 according to endometriotic lesions.…”

Section: Discussionmentioning

confidence: 99%

Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours

et al. 2003

View full text Add to dashboard Cite

Apoptosis is a physiological process by which multicellular organisms eliminate superfluous cells. Alterations in apoptosis play a key role in tumour development. The objective was to evaluate the immunohistochemical expression of p53, p21, bax, bak, fas, bcl-2 and bcl-x proteins in 10 endometriomas, 20 benign ovarian tumours (10 mucinous, 10 serous) and 30 malignant ovarian tumours (9 mucinous, 19 serous; 2 endometrioids). p53 positive cells (mean+/-SD) in endometriomas, and benign and malignant tumours were 1.9+/-3.2, 0 and 16.2+/-33.0, respectively. The difference was significant between benign tumours and endometriomas (P=0.003) but not between endometriomas and malignant tumours. P21 expression in endometriomas and benign and malignant tumours was 19.5+/-27.8, 1.7+/-6.7 and 4.1+/-8.6, respectively. Increased p21 expression was found in endometriomas compared with benign (P=0.001) and malignant (P=0.01) tumours. Bax expression was higher in endometriomas than in benign tumours (P=0.01), but no difference was found between endometriomas and malignant tumours. No difference in bak, fas, bcl-2 or bcl-x expression was observed among the groups. In endometriomas, a negative correlation was found between p53 and fas expression (P=0.04, r=0.66). Although endometriomas have histological features of benign ovarian tumours, endometriomas share with malignant ovarian tumours certain alterations in apoptosis-related proteins.

show abstract

Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours

Cited by 33 publications

References 0 publications

Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours

Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours

Contact Info

Product

Resources

About